| Recruiting | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T- NCT07137416 | National Cancer Institute (NCI) | Phase 1 |
| Not Yet Recruiting | Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor R NCT05741164 | Emory University | Phase 2 |
| Recruiting | A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Tri NCT07078604 | University of Washington | Phase 2 |
| Recruiting | Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Loc NCT06434064 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative B NCT06324240 | Emory University | Phase 1 |
| Recruiting | High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Posit NCT06492759 | Emory University | Phase 2 |
| Recruiting | Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer NCT06774027 | University of California, San Francisco | — |
| Withdrawn | Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Tre NCT06590558 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negat NCT05539365 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | Neratinib in Combination With Ruxolitinib in Patients With mTNBC NCT06008275 | Baylor Research Institute | EARLY_Phase 1 |
| Recruiting | Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Trea NCT06505018 | UNICANCER | N/A |
| Terminated | Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastat NCT05756166 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | A Study of Pembrolizumab and Cryoablation in People With Breast Cancer NCT06246968 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs NCT06176261 | Sarah Sammons, MD | Phase 2 |
| Recruiting | Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast NCT05318469 | Yuan Yuan | Phase 1 / Phase 2 |
| Recruiting | Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) NCT05673200 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy NCT05770531 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Withdrawn | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer NCT05368506 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Terminated | Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer NCT05742269 | Karolinska University Hospital | — |
| Recruiting | Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard NCT05422794 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple NCT04348747 | Roswell Park Cancer Institute | Phase 2 |
| Withdrawn | SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Can NCT05093387 | Northwestern University | Phase 1 |
| Recruiting | Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS NCT05451784 | Fundacio Clinic Barcelona | Phase 1 / Phase 2 |
| Unknown | Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast NCT04634747 | OncoPep, Inc. | Phase 2 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer NCT05081492 | City of Hope Medical Center | Phase 1 |
| Terminated | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab NCT04639245 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients NCT03606967 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer NCT04345913 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases NCT04789668 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC NCT04664829 | National Cancer Centre, Singapore | Phase 1 |
| Active Not Recruiting | INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study NCT04445844 | Mridula George, MD | Phase 2 |
| Withdrawn | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer NCT04249167 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Ca NCT03941730 | Mayo Clinic | Phase 2 |
| Completed | Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating NCT03853707 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Active Not Recruiting | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy NCT03589339 | Nanobiotix | Phase 1 |
| Terminated | AMTEC IIT: Phase 2 Multiarm Study in TNBC NCT03801369 | Gordon Mills, MD, PhD | Phase 2 |
| Terminated | M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer NCT03579472 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast NCT03106415 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Br NCT02971761 | City of Hope Medical Center | Phase 2 |
| Completed | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surg NCT02898207 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or B NCT02595905 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors NCT02498613 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies NCT02706392 | Fred Hutchinson Cancer Center | Phase 1 |
| Approved For Marketing | Expanded Access for IMMU-132 NCT04320693 | Gilead Sciences | — |
| No Longer Available | A Compassionate Use Study of Leronlimab in Breast Cancer NCT04313075 | CytoDyn, Inc. | — |